Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000932471-25-001028·Sage Therapeutics, Inc.
Schedule 13G ownership disclosure
N/A
Common Stock · CUSIP: 78667J108
Event date: 2025-06-30
- Filing-level shares
- 3,265,802
- Percent of class
- 5.21%
- The Vanguard Group
Shares: 3,265,802 · Class: 5.21%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-25-001028
- Form type
- SCHEDULE 13G/A
- Filer
- Sage Therapeutics, Inc.
- CIK
- CIK 1597553
- Filed
- Jul 29, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership